{
  "meta": {
    "id": "test11",
    "title": "Hematology",
    "category": "Subject Wise / Mixed"
  },
  "questions": [
    {
      "text": "Which of the following is given to treat thrombocytopenia secondary to anti-cancer therapy and is known to stimulate progenitor megakaryocytes?",
      "options": [
        {
          "label": "A",
          "text": "Filgrastim",
          "correct": false
        },
        {
          "label": "B",
          "text": "Oprelvekin",
          "correct": true
        },
        {
          "label": "C",
          "text": "Erythropoietin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Iron dextran",
          "correct": false
        }
      ],
      "correct_answer": "B. Oprelvekin",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/picture3.jpg"
      ],
      "explanation": "<p><strong>Ans. B. Oprelvekin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Filgrastim: Filgrastim is a granulocyte colony-stimulating factor (G-CSF) that is used to increase neutrophil counts in patients undergoing chemotherapy. It stimulates the production of white blood cells, not platelets, and is therefore used to treat or prevent neutropenia , not thrombocytopenia.</li><li>\u2022 Option A. Filgrastim:</li><li>\u2022 granulocyte colony-stimulating factor (G-CSF)</li><li>\u2022 increase neutrophil counts</li><li>\u2022 undergoing chemotherapy.</li><li>\u2022 stimulates</li><li>\u2022 white blood cells,</li><li>\u2022 used to treat</li><li>\u2022 prevent neutropenia</li><li>\u2022 Option C. Erythropoietin: Erythropoietin is a glycoprotein hormone that stimulates erythropoiesis, or red blood cell production, in the bone marrow . It is used to treat anemia, particularly in chronic kidney disease and in patients undergoing chemotherapy. It does not directly increase platelet counts.</li><li>\u2022 Option C. Erythropoietin:</li><li>\u2022 glycoprotein hormone</li><li>\u2022 stimulates erythropoiesis,</li><li>\u2022 red blood cell production,</li><li>\u2022 bone marrow</li><li>\u2022 used to</li><li>\u2022 anemia,</li><li>\u2022 chronic kidney disease</li><li>\u2022 undergoing chemotherapy.</li><li>\u2022 does not</li><li>\u2022 increase platelet counts.</li><li>\u2022 Option D. Iron dextran: Iron dextran is an intravenous iron supplement used to treat iron deficiency anemia. It does not stimulate the production of platelets or megakaryocyte progenitors and is not used to treat thrombocytopenia secondary to anticancer therapy.</li><li>\u2022 Option D. Iron dextran:</li><li>\u2022 intravenous iron supplement</li><li>\u2022 iron deficiency anemia.</li><li>\u2022 does not</li><li>\u2022 platelets or megakaryocyte progenitors</li><li>\u2022 not used</li><li>\u2022 thrombocytopenia secondary to anticancer therapy.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational objective is to understand the hematopoietic growth factors and their role in treatment options for adverse effects of anticancer drugs .  and to recognize that oprelvekin is used for its ability to stimulate progenitor megakaryocytes , leading to an increase in platelet production.</li><li>\u27a4 hematopoietic growth factors</li><li>\u27a4 treatment</li><li>\u27a4 adverse effects</li><li>\u27a4 anticancer drugs</li><li>\u27a4 oprelvekin</li><li>\u27a4 used for its ability to stimulate progenitor megakaryocytes</li><li>\u27a4 increase in platelet production.</li><li>\u27a4 Hematopoietic Growth Factors:</li><li>\u27a4 Hematopoietic Growth Factors:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f1474ae0",
      "audio": ""
    },
    {
      "text": "Which of the following statements about erythropoietin is false?",
      "options": [
        {
          "label": "A",
          "text": "It is used for the treatment of anaemia due to chronic renal failure.",
          "correct": false
        },
        {
          "label": "B",
          "text": "It results in decrease in reticulocyte count.",
          "correct": true
        },
        {
          "label": "C",
          "text": "It decreases the requirement of blood transfusions.",
          "correct": false
        },
        {
          "label": "D",
          "text": "It can cause hypertension.",
          "correct": false
        }
      ],
      "correct_answer": "B. It results in decrease in reticulocyte count.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. It results in decrease in reticulocyte count.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Correct. Erythropoietin is used to treat anaemia due to chronic renal failure because the kidneys in such patients do not produce enough endogenous erythropoietin.</li><li>\u2022 Option A.</li><li>\u2022 Correct.</li><li>\u2022 Erythropoietin</li><li>\u2022 treat anaemia</li><li>\u2022 chronic renal failure</li><li>\u2022 kidneys</li><li>\u2022 do not</li><li>\u2022 endogenous erythropoietin.</li><li>\u2022 Option C: Correct. By stimulating red blood cell production, erythropoietin reduces the need for blood transfusions.</li><li>\u2022 Option C:</li><li>\u2022 Correct.</li><li>\u2022 stimulating red blood cell production,</li><li>\u2022 erythropoietin</li><li>\u2022 reduces</li><li>\u2022 blood transfusions.</li><li>\u2022 Option D: Correct. Erythropoietin can sometimes cause hypertension as a side effect because of the increased red blood cell mass and possibly other mechanisms.</li><li>\u2022 Option D:</li><li>\u2022 Correct.</li><li>\u2022 Erythropoietin</li><li>\u2022 hypertension</li><li>\u2022 side effect</li><li>\u2022 increased red blood cell mass</li><li>\u2022 possibly</li><li>\u2022 mechanisms.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Erythropoietin treatment should result in an increased reticulocyte count, reflecting the stimulated production of red blood cells . It is beneficial in chronic renal failure-related anaemia and can help decrease the need for transfusions, although it may cause hypertension as a side effect.</li><li>\u2022 Erythropoietin</li><li>\u2022 increased reticulocyte count,</li><li>\u2022 stimulated production of red blood cells</li><li>\u2022 beneficial in chronic renal failure-related anaemia</li><li>\u2022 decrease</li><li>\u2022 transfusions,</li><li>\u2022 hypertension</li><li>\u2022 side effect.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7ac099c9",
      "audio": ""
    },
    {
      "text": "A 65-year-old patient, with a history of hypertension and type 2 diabetes, recently underwent total hip replacement surgery. Post-operatively, the healthcare team is focused on preventing venous thromboembolism (VTE), a common complication after such surgeries. Given the patient's increased risk for VTE due to surgery, immobility, and underlying conditions, the decision to initiate thromboprophylaxis with low molecular weight (LMW) heparin was made. Route of administration of LMW heparin in this patient is",
      "options": [
        {
          "label": "A",
          "text": "Intramuscular",
          "correct": false
        },
        {
          "label": "B",
          "text": "Subcutaneous",
          "correct": true
        },
        {
          "label": "C",
          "text": "Intravenous",
          "correct": false
        },
        {
          "label": "D",
          "text": "Inhalational",
          "correct": false
        }
      ],
      "correct_answer": "B. Subcutaneous",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. Subcutaneous</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Intramuscular: LMW heparin is not administered intramuscularly due to the risk of hematoma formation in the muscle, which can be particularly problematic in patients with a heightened risk of bleeding or those who are receiving anticoagulation therapy.</li><li>\u2022 Option A. Intramuscular:</li><li>\u2022 LMW heparin</li><li>\u2022 not</li><li>\u2022 intramuscularly</li><li>\u2022 risk of hematoma formation in the muscle,</li><li>\u2022 heightened risk of bleeding</li><li>\u2022 receiving anticoagulation</li><li>\u2022 therapy.</li><li>\u2022 Option C. Intravenous: While LMW heparin can be administered intravenously, this route is not typically used for thromboprophylaxis in the post-operative setting. Intravenous administration is more common for unfractionated heparin, which requires monitoring of the anticoagulant effect and is used in acute settings.</li><li>\u2022 Option C. Intravenous:</li><li>\u2022 LMW heparin</li><li>\u2022 administered intravenously,</li><li>\u2022 not</li><li>\u2022 thromboprophylaxis</li><li>\u2022 post-operative setting.</li><li>\u2022 unfractionated heparin,</li><li>\u2022 monitoring of the anticoagulant effect</li><li>\u2022 acute settings.</li><li>\u2022 Option D. Inhalational: This route is not applicable to LMW heparin as it i s not designed for inhalation. The inhalational route of administration is used for drugs intended to act directly on the lungs.</li><li>\u2022 Option D. Inhalational:</li><li>\u2022 not</li><li>\u2022 applicable to LMW heparin</li><li>\u2022 s not designed for inhalation.</li><li>\u2022 inhalational</li><li>\u2022 drugs</li><li>\u2022 act directly on the lungs.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational objective is to understand the appropriate route of administration for low molecular weight heparin in the context of thromboprophylaxis in post-operative patients . Subcutaneous administration is the preferred and recommended route because it offers consistent absorption and effective prevention of VTE without the need for routine anticoagulation monitoring , minimizing the risk of complications associated with other routes of administration.</li><li>\u27a4 appropriate route of administration for low molecular weight heparin</li><li>\u27a4 thromboprophylaxis in post-operative patients</li><li>\u27a4 Subcutaneous</li><li>\u27a4 preferred and recommended route</li><li>\u27a4 consistent absorption and effective prevention</li><li>\u27a4 VTE without</li><li>\u27a4 anticoagulation monitoring</li><li>\u27a4 minimizing the risk of complications</li><li>\u27a4 other routes of administration.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ae133135",
      "audio": ""
    },
    {
      "text": "Which of the following drugs is used postoperatively to reverse the effect of heparin used intraoperatively in cardiac surgery?",
      "options": [
        {
          "label": "A",
          "text": "Protamine sulphate",
          "correct": true
        },
        {
          "label": "B",
          "text": "Vitamin K",
          "correct": false
        },
        {
          "label": "C",
          "text": "Tranexamic acid",
          "correct": false
        },
        {
          "label": "D",
          "text": "Factor VIII concentrate",
          "correct": false
        }
      ],
      "correct_answer": "A. Protamine sulphate",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. Protamine sulphate</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Vitamin K: Incorrect because Vitamin K is used to reverse the effects of warfarin , not heparin.</li><li>\u2022 Option B. Vitamin K:</li><li>\u2022 Incorrect</li><li>\u2022 Vitamin K</li><li>\u2022 reverse the effects of warfarin</li><li>\u2022 Option C. Tranexamic acid: Incorrect as it is used to reduce bleeding by inhibiting fibrinolysis, not reversing heparin.</li><li>\u2022 Option C. Tranexamic acid:</li><li>\u2022 Incorrect</li><li>\u2022 reduce bleeding by inhibiting fibrinolysis,</li><li>\u2022 Option D. Factor VIII concentrate: Incorrect as it is used in the treatment of hemophilia A, not for reversing heparin effects.</li><li>\u2022 Option D. Factor VIII concentrate:</li><li>\u2022 Incorrect</li><li>\u2022 treatment of hemophilia A,</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Protamine sulphate is the drug of choice for reversing the anticoagulant effects of heparin following cardiac surgeries or other procedures where heparin has been used . It works by binding to and neutralizing heparin.</li><li>\u2022 Protamine sulphate</li><li>\u2022 drug of choice</li><li>\u2022 reversing the anticoagulant effects of heparin</li><li>\u2022 cardiac surgeries</li><li>\u2022 procedures</li><li>\u2022 heparin has been used</li><li>\u2022 binding to and neutralizing heparin.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f0cf0744",
      "audio": ""
    },
    {
      "text": "Which of the following drugs is least likely to precipitate megaloblastic anaemia in a patient with subclinical folate deficiency?",
      "options": [
        {
          "label": "A",
          "text": "Alcohol",
          "correct": false
        },
        {
          "label": "B",
          "text": "Phenytoin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Chloroquine",
          "correct": true
        },
        {
          "label": "D",
          "text": "Sulfasalazine",
          "correct": false
        }
      ],
      "correct_answer": "C. Chloroquine",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/picture2.jpg"
      ],
      "explanation": "<p><strong>Ans. C. Chloroquine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A: Chronic alcohol use can lead to various nutritional deficiencies, including folate deficiency, because of poor diet, malabsorption , and ethanol's interference with folate metabolism.</li><li>\u2022 Option A:</li><li>\u2022 Chronic alcohol</li><li>\u2022 lead</li><li>\u2022 nutritional deficiencies,</li><li>\u2022 folate deficiency,</li><li>\u2022 poor diet,</li><li>\u2022 malabsorption</li><li>\u2022 ethanol's</li><li>\u2022 folate metabolism.</li><li>\u2022 Option B: Phenytoin, a widely used anticonvulsant, can impair the absorption of folate and lead to megaloblastic anemia, particularly if folate reserves are already compromised.</li><li>\u2022 Option B:</li><li>\u2022 Phenytoin,</li><li>\u2022 anticonvulsant,</li><li>\u2022 absorption of folate</li><li>\u2022 megaloblastic anemia,</li><li>\u2022 folate reserves</li><li>\u2022 compromised.</li><li>\u2022 Option D: Sulfasalazine, used in the treatment of inflammatory bowel diseases , can also impair folate absorption and contribute to the development of megaloblastic anemia.</li><li>\u2022 Option D:</li><li>\u2022 Sulfasalazine,</li><li>\u2022 inflammatory bowel diseases</li><li>\u2022 impair folate absorption</li><li>\u2022 development of megaloblastic anemia.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 In the context of drugs that may exacerbate or precipitate megaloblastic anemia due to folate deficiency , chloroquine is not associated with interference in folate metabolism and is thus the least likely to cause this condition among the options listed.</li><li>\u2022 exacerbate or precipitate megaloblastic anemia</li><li>\u2022 folate deficiency</li><li>\u2022 chloroquine</li><li>\u2022 not</li><li>\u2022 interference in folate metabolism</li><li>\u2022 least likely</li><li>\u2022 DRUGS CAUSING MEGALOBLASTIC ANEMIA</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6fbdcb10",
      "audio": ""
    },
    {
      "text": "All the following drugs increase bleeding when given to a patient on warfarin except?",
      "options": [
        {
          "label": "A",
          "text": "Isoniazid",
          "correct": false
        },
        {
          "label": "B",
          "text": "Amiodarone",
          "correct": false
        },
        {
          "label": "C",
          "text": "Carbamazepine",
          "correct": true
        },
        {
          "label": "D",
          "text": "Cimetidine",
          "correct": false
        }
      ],
      "correct_answer": "C. Carbamazepine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. Carbamazepine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A: Isoniazid: Isoniazid is an inhibitor of CYP2C9 , which can inhibit the metabolism of warfarin. This inhibition leads to increased plasma concentration of warfarin , thereby increasing the risk of bleeding.</li><li>\u2022 Option A: Isoniazid:</li><li>\u2022 inhibitor of CYP2C9</li><li>\u2022 inhibit the metabolism of warfarin.</li><li>\u2022 inhibition leads to</li><li>\u2022 increased plasma concentration of warfarin</li><li>\u2022 increasing the risk of bleeding.</li><li>\u2022 Option B: Amiodarone: Amiodarone is also an inhibitor of CYP2C9. Like isoniazid, it inhibits the metabolism of warfarin, leading to increased plasma concentration and an increased risk of bleeding.</li><li>\u2022 Option B: Amiodarone:</li><li>\u2022 inhibitor of CYP2C9.</li><li>\u2022 inhibits the metabolism of warfarin,</li><li>\u2022 increased plasma concentration</li><li>\u2022 increased risk of bleeding.</li><li>\u2022 Option D: Cimetidine: Cimetidine is yet another inhibitor of CYP2C9. As with isoniazid and amiodarone, it inhibits the metabolism of warfarin, resulting in elevated plasma concentrations and an increased likelihood of bleeding.</li><li>\u2022 Option D: Cimetidine:</li><li>\u2022 Cimetidine</li><li>\u2022 inhibitor of CYP2C9.</li><li>\u2022 isoniazid and amiodarone,</li><li>\u2022 inhibits the metabolism</li><li>\u2022 warfarin,</li><li>\u2022 elevated plasma concentrations</li><li>\u2022 increased</li><li>\u2022 bleeding.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Carbamazepine, as an enzyme inducer, decreases the plasma concentration of warfarin, reducing the risk of bleeding when used concomitantly.</li><li>\u2022 Carbamazepine,</li><li>\u2022 enzyme inducer, decreases</li><li>\u2022 plasma concentration of warfarin, reducing</li><li>\u2022 risk of bleeding</li><li>\u2022 used</li><li>\u2022 concomitantly.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b2e0559b",
      "audio": ""
    },
    {
      "text": "Which of the following anticoagulant therapy needs regular monitoring?",
      "options": [
        {
          "label": "A",
          "text": "Enoxaparin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Argatroban",
          "correct": true
        },
        {
          "label": "C",
          "text": "Dabigatran",
          "correct": false
        },
        {
          "label": "D",
          "text": "Fondaparinux",
          "correct": false
        }
      ],
      "correct_answer": "B. Argatroban",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/picture6.jpg"
      ],
      "explanation": "<p><strong>Ans. B. Argatroban</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Enoxaparin: Enoxaparin is a low molecular weight heparin (LMWH) used for the prevention and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). While it has a mor e predictable dose-response relationship compared to unfractionated heparin , routine laboratory monitoring for anticoagulation effect is generally not required in most patients.</li><li>\u2022 Option A. Enoxaparin:</li><li>\u2022 low molecular weight heparin</li><li>\u2022 prevention and treatment of deep vein</li><li>\u2022 thrombosis (DVT) and pulmonary embolism (PE).</li><li>\u2022 mor</li><li>\u2022 dose-response</li><li>\u2022 unfractionated heparin</li><li>\u2022 laboratory monitoring</li><li>\u2022 not required in most patients.</li><li>\u2022 Option C. Dabigatran: Dabigatran is a direct oral anticoagulant (DOAC) that inhibits thrombin. It is used for stroke prevention in non-valvular atrial fibrillation and treatment of DVT and PE, among other indications. Dabigatran offers the advantage of fixed dosing without the need for routine coagulation monitoring.</li><li>\u2022 Option C. Dabigatran:</li><li>\u2022 direct oral anticoagulant (DOAC)</li><li>\u2022 inhibits thrombin.</li><li>\u2022 used</li><li>\u2022 stroke prevention</li><li>\u2022 non-valvular atrial fibrillation</li><li>\u2022 treatment of DVT</li><li>\u2022 PE,</li><li>\u2022 Dabigatran</li><li>\u2022 fixed dosing without</li><li>\u2022 routine coagulation monitoring.</li><li>\u2022 Option D. Fondaparinux: Fondaparinux is a synthetic pentasaccharide that inhibits factor Xa indirectly by binding to antithrombin . It is used for DVT prevention and treatment and for preventing PE. Like LMWH, fondaparinux generally does not require routine monitoring due to its predictable pharmacokinetic profile.</li><li>\u2022 Option D. Fondaparinux:</li><li>\u2022 synthetic pentasaccharide</li><li>\u2022 inhibits factor Xa indirectly</li><li>\u2022 binding to antithrombin</li><li>\u2022 DVT prevention and treatment</li><li>\u2022 preventing PE. Like LMWH, fondaparinux</li><li>\u2022 does not</li><li>\u2022 routine</li><li>\u2022 monitoring</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational objective is to understand which anticoagulant therapies require regular monitoring and which does not.</li><li>\u27a4 understand</li><li>\u27a4 anticoagulant therapies</li><li>\u27a4 regular monitoring</li><li>\u27a4 does not.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0742f303",
      "audio": ""
    },
    {
      "text": "Which of the following is orally active direct Xa inhibitor?",
      "options": [
        {
          "label": "A",
          "text": "Rivaroxaban",
          "correct": true
        },
        {
          "label": "B",
          "text": "Argatroban",
          "correct": false
        },
        {
          "label": "C",
          "text": "Dabigatran",
          "correct": false
        },
        {
          "label": "D",
          "text": "Bivalirudin",
          "correct": false
        }
      ],
      "correct_answer": "A. Rivaroxaban",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/picture8.jpg"
      ],
      "explanation": "<p><strong>Ans. A. Rivaroxaban</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Option B. Argatroban : Argatroban is a direct thrombin inhibitor, not a Factor Xa inhibitor. It is administered intravenously and is used primarily in patients with heparin-induced thrombocytopenia (HIT).</li><li>\u2022 Option B. Argatroban</li><li>\u2022 direct thrombin inhibitor,</li><li>\u2022 intravenously</li><li>\u2022 used</li><li>\u2022 heparin-induced thrombocytopenia (HIT).</li><li>\u2022 Option C. Dabigatran: Dabigatran is also a direct thrombin inhibitor but differs from argatroban in that it is orally active . It is not a Factor Xa inhibitor.</li><li>\u2022 Option C. Dabigatran:</li><li>\u2022 Dabigatran</li><li>\u2022 direct thrombin inhibitor</li><li>\u2022 differs from argatroban</li><li>\u2022 orally active</li><li>\u2022 not</li><li>\u2022 Factor Xa inhibitor.</li><li>\u2022 Option D. Bivalirudin: Bivalirudin is another direct thrombin inhibitor, used intravenously, particularly in patients undergoing percutaneous coronary intervention (PCI). It is not a Factor Xa inhibitor and not orally active.</li><li>\u2022 Option D. Bivalirudin:</li><li>\u2022 Bivalirudin</li><li>\u2022 another direct thrombin inhibitor,</li><li>\u2022 intravenously,</li><li>\u2022 percutaneous coronary intervention (PCI).</li><li>\u2022 not</li><li>\u2022 Factor Xa inhibitor</li><li>\u2022 not orally active.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational objective is to recognize the classification of anticoagulant drugs , specifically identifying rivaroxaban as an orally active direct Factor Xa inhibitor.</li><li>\u27a4 classification of anticoagulant drugs</li><li>\u27a4 rivaroxaban</li><li>\u27a4 orally active direct Factor Xa inhibitor.</li><li>\u27a4 Classification of Anticoagulants</li><li>\u27a4 Classification of Anticoagulants</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b04113ef",
      "audio": ""
    },
    {
      "text": "Which of the following statements is true about warfarin?",
      "options": [
        {
          "label": "A",
          "text": "Act through inhibition of coagulation factor VIII",
          "correct": false
        },
        {
          "label": "B",
          "text": "Protamine sulphate reverses its action.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Monitoring is done through INR.",
          "correct": true
        },
        {
          "label": "D",
          "text": "Target INR for patients of Pulmonary embolism on warfarin therapy is generally 6-8",
          "correct": false
        }
      ],
      "correct_answer": "C. Monitoring is done through INR.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. Monitoring is done through INR.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Act through inhibition of coagulation factor VIII: Warfarin primarily inhibits the synthesis of vitamin K-dependent clotting factors II, VII, IX, and X in the liver . It does not specifically target factor VIII. Therefore, this statement is incorrect.</li><li>\u2022 Option A.</li><li>\u2022 Act through inhibition of coagulation factor VIII:</li><li>\u2022 Warfarin</li><li>\u2022 inhibits the synthesis of vitamin K-dependent clotting</li><li>\u2022 factors II, VII, IX, and X in the liver</li><li>\u2022 does not</li><li>\u2022 factor VIII.</li><li>\u2022 incorrect.</li><li>\u2022 Option B. Protamine sulphate reverses its action: Protamine sulfate is a specific antidote for heparin, not warfarin. Warfarin's anticoagulant effect can be reversed with vitamin K or prothrombin complex concentrate s. Therefore, this statement is incorrect.</li><li>\u2022 Option B. Protamine sulphate reverses its action:</li><li>\u2022 Protamine sulfate</li><li>\u2022 specific antidote</li><li>\u2022 heparin, not warfarin.</li><li>\u2022 reversed with vitamin K</li><li>\u2022 prothrombin complex concentrate</li><li>\u2022 incorrect.</li><li>\u2022 Option D. Target INR for patients of Pulmonary embolism on warfarin therapy is generally 6-8: The target INR range for patients on warfarin therapy depends on the indication, but a target INR of 6-8 is excessively high and associated with an increased risk of bleeding . For most indications, including pulmonary embolism, the target INR range is typically 2.0-3.0. Therefore, this statement is incorrect.</li><li>\u2022 Option D. Target INR for patients of Pulmonary embolism on warfarin therapy is generally 6-8:</li><li>\u2022 target INR</li><li>\u2022 warfarin therapy</li><li>\u2022 indication,</li><li>\u2022 target INR of 6-8 is excessively high</li><li>\u2022 increased risk of</li><li>\u2022 bleeding</li><li>\u2022 pulmonary embolism,</li><li>\u2022 target INR range</li><li>\u2022 2.0-3.0.</li><li>\u2022 incorrect.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Monitoring of warfarin therapy is done through the International Normalized Ratio (INR), which is a standardized measure of the patient's prothrombin time (PT) compared to a normal control.</li><li>\u2022 Monitoring of warfarin therapy</li><li>\u2022 International Normalized Ratio (INR),</li><li>\u2022 standardized</li><li>\u2022 prothrombin time (PT)</li><li>\u2022 normal control.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2d3b2718",
      "audio": ""
    },
    {
      "text": "Which of the following anticoagulant and its FDA approved antidote is not correctly matched?",
      "options": [
        {
          "label": "A",
          "text": "Idarucizumab- dabigatran",
          "correct": false
        },
        {
          "label": "B",
          "text": "Andexanet alfa- rivaroxaban",
          "correct": false
        },
        {
          "label": "C",
          "text": "Ciraparantag- fondaparinux",
          "correct": true
        },
        {
          "label": "D",
          "text": "Andexanet- apixaban",
          "correct": false
        }
      ],
      "correct_answer": "C. Ciraparantag- fondaparinux",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/picture15.jpg"
      ],
      "explanation": "<p><strong>Ans. C. Ciraparantag- fondaparinux</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Idarucizumab- dabigatran: Idarucizumab is a monoclonal antibody that is the approved antidote for dabigatran . It reverses the anticoagulant effect of dabigatran by binding to it with high affinity.</li><li>\u2022 Option A. Idarucizumab- dabigatran:</li><li>\u2022 monoclonal antibody</li><li>\u2022 antidote for dabigatran</li><li>\u2022 reverses the anticoagulant</li><li>\u2022 dabigatran</li><li>\u2022 binding to it</li><li>\u2022 high affinity.</li><li>\u2022 Option B. Andexanet alfa- rivaroxaban: Andexanet alfa is a recombinant modified human factor Xa decoy protein that acts as an antidote to factor Xa inhibitors, including rivaroxaban.</li><li>\u2022 Option B. Andexanet alfa- rivaroxaban:</li><li>\u2022 Andexanet alfa</li><li>\u2022 recombinant modified</li><li>\u2022 Xa decoy protein</li><li>\u2022 acts</li><li>\u2022 antidote to factor Xa inhibitors,</li><li>\u2022 rivaroxaban.</li><li>\u2022 Option D. Andexanet- apixaban: Andexanet alfa is also the approved antidote for apixaban, reversing its anticoagulant effect by acting as a decoy for the drug.</li><li>\u2022 Option D. Andexanet- apixaban:</li><li>\u2022 Andexanet alfa</li><li>\u2022 antidote for apixaban,</li><li>\u2022 its anticoagulant effect</li><li>\u2022 decoy for the drug.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational objective is to know the specific antidotes for various anticoagulants and to be aware of the correct pairing between these antidotes and their corresponding drugs.</li><li>\u27a4 specific antidotes for various anticoagulants</li><li>\u27a4 correct pairing</li><li>\u27a4 between</li><li>\u27a4 these antidotes</li><li>\u27a4 corresponding drugs.</li><li>\u27a4 Antidotes for anticoagulants (DOAC)</li><li>\u27a4 Antidotes for anticoagulants (DOAC)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "dd6c65f8",
      "audio": ""
    },
    {
      "text": "Which of the following is not a prodrug?",
      "options": [
        {
          "label": "A",
          "text": "Ticlopidine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Ticagrelor",
          "correct": true
        },
        {
          "label": "C",
          "text": "Clopidogrel",
          "correct": false
        },
        {
          "label": "D",
          "text": "Prasugrel",
          "correct": false
        }
      ],
      "correct_answer": "B. Ticagrelor",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. Ticagrelor</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Ticlopidine: Ticlopidine is a thienopyridine antiplatelet agent , similar to clopidogrel and prasugrel, and is a prodrug. It requires metabolic activation by the liver to form its active metabolite , which then inhibits the P2Y12 adenosine diphosphate (ADP ) r eceptor on platelets, preventing platelet activation and aggregation.</li><li>\u2022 Option A. Ticlopidine:</li><li>\u2022 thienopyridine antiplatelet agent</li><li>\u2022 similar</li><li>\u2022 clopidogrel and prasugrel,</li><li>\u2022 metabolic activation</li><li>\u2022 liver</li><li>\u2022 active metabolite</li><li>\u2022 inhibits the P2Y12 adenosine diphosphate (ADP</li><li>\u2022 eceptor on platelets, preventing platelet activation and aggregation.</li><li>\u2022 Option C. Clopidogrel: Clopidogrel is another thienopyridine class antiplatelet medication and a prodrug. It requires hepatic biotransformation to an active metabolite that inhibits the P2Y12 component of ADP receptors on the surface of platelets , reducing platelet aggregation.</li><li>\u2022 Option C. Clopidogrel:</li><li>\u2022 thienopyridine</li><li>\u2022 antiplatelet medication</li><li>\u2022 prodrug.</li><li>\u2022 hepatic</li><li>\u2022 biotransformation</li><li>\u2022 active metabolite</li><li>\u2022 inhibits the P2Y12 component of ADP receptors on the surface of platelets</li><li>\u2022 reducing platelet aggregation.</li><li>\u2022 Option D. Prasugrel: Prasugrel is also a thienopyridine antiplatelet drug and a prodrug . It is rapidly metabolized to its active metabolite in the body, which then irreversibly binds to the P2Y12 receptor on platelets, inhibiting platelet activation and aggregation more efficiently and consistently than clopidogrel.</li><li>\u2022 Option D. Prasugrel:</li><li>\u2022 thienopyridine antiplatelet drug</li><li>\u2022 prodrug</li><li>\u2022 rapidly metabolized</li><li>\u2022 its active</li><li>\u2022 metabolite</li><li>\u2022 irreversibly binds</li><li>\u2022 P2Y12 receptor on platelets,</li><li>\u2022 inhibiting platelet activation</li><li>\u2022 aggregation</li><li>\u2022 more efficiently</li><li>\u2022 clopidogrel.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational objective is to identify the antiplatelet agent that is not a prodrug among the options provided. Understanding the distinction between prodrugs and drugs that are active in their administered form is crucial for pharmacological knowledge, especially in the context of antiplatelet therapy . Prodrugs require metabolic activation to exert their pharmacological effects, whereas drugs like ticagrelor are active upon administration, offering a different profile of onset, duration, and potentially side effect profiles, which can impact clinical decisions in the management of cardiovascular diseases.</li><li>\u27a4 identify the antiplatelet agent</li><li>\u27a4 not a prodrug</li><li>\u27a4 distinction</li><li>\u27a4 prodrugs and drugs</li><li>\u27a4 active in their administered form</li><li>\u27a4 pharmacological knowledge,</li><li>\u27a4 . Prodrugs</li><li>\u27a4 metabolic activation</li><li>\u27a4 pharmacological effects,</li><li>\u27a4 ticagrelor are active upon administration,</li><li>\u27a4 different profile of onset, duration, and potentially side</li><li>\u27a4 effect profiles,</li><li>\u27a4 clinical decisions</li><li>\u27a4 cardiovascular diseases.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a8d63645",
      "audio": ""
    },
    {
      "text": "Which of the following statements is correct about heparin-induced thrombocytopenia (HIT)?",
      "options": [
        {
          "label": "A",
          "text": "HIT is a bleeding disorder caused by a deficiency of von Willebrand factor (vWF)",
          "correct": false
        },
        {
          "label": "B",
          "text": "HIT is a rare condition that only occurs in patients with a history of thrombosis",
          "correct": false
        },
        {
          "label": "C",
          "text": "HIT is caused by the formation of antibodies against platelet factor 4 (PF4) complexed with heparin.",
          "correct": true
        },
        {
          "label": "D",
          "text": "HIT is characterized by a normal platelet count and increased risk of bleeding.",
          "correct": false
        }
      ],
      "correct_answer": "C. HIT is caused by the formation of antibodies against platelet factor 4 (PF4) complexed with heparin.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. HIT is caused by the formation of antibodies against platelet factor 4 (PF4) complexed with heparin.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A: Incorrect . HIT is not related to von Willebrand factor (vWF) ; vWF deficiency causes von Willebrand disease, a different bleeding disorder.</li><li>\u2022 Option A:</li><li>\u2022 Incorrect</li><li>\u2022 HIT</li><li>\u2022 not</li><li>\u2022 von Willebrand factor (vWF)</li><li>\u2022 vWF deficiency</li><li>\u2022 von Willebrand disease,</li><li>\u2022 different</li><li>\u2022 bleeding disorder.</li><li>\u2022 Option B: Incorrect . HIT can occur in any patient receiving heparin, not just those with a history of thrombosis.</li><li>\u2022 Option B:</li><li>\u2022 Incorrect</li><li>\u2022 HIT</li><li>\u2022 patient receiving heparin, not</li><li>\u2022 history of thrombosis.</li><li>\u2022 Option D: Incorrect . HIT is characterized by a decreased platelet count (thrombocytopenia) , not a normal count, and it is associated with an increased risk of thrombosis, not bleeding.</li><li>\u2022 Option D:</li><li>\u2022 Incorrect</li><li>\u2022 HIT</li><li>\u2022 decreased platelet count (thrombocytopenia)</li><li>\u2022 not</li><li>\u2022 normal count,</li><li>\u2022 increased risk of thrombosis, not bleeding.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Heparin-induced thrombocytopenia (HIT) is a serious and potentially life-threatening condition characterized by the formation of antibodies to complexes formed between heparin and PF4, leading to platelet activation and an increased risk of thrombosis despite a decrease in platelet count . Management involves discontinuation of heparin and initiation of alternative anticoagulation with agents like direct thrombin inhibitors.</li><li>\u2022 Heparin-induced thrombocytopenia (HIT)</li><li>\u2022 serious</li><li>\u2022 life-threatening condition</li><li>\u2022 formation of</li><li>\u2022 antibodies</li><li>\u2022 heparin and PF4,</li><li>\u2022 platelet activation and an increased risk of thrombosis</li><li>\u2022 decrease in platelet count</li><li>\u2022 discontinuation of heparin and initiation of alternative anticoagulation</li><li>\u2022 direct thrombin inhibitors.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "75df15a6",
      "audio": ""
    },
    {
      "text": "Which of the following statements is true regarding iron replacement therapy for iron deficiency anaemia?",
      "options": [
        {
          "label": "A",
          "text": "Oral iron should be given until haematocrit normalizes and then discontinued due to gastric adverse effects.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Before administering parenteral iron, the dose should be diluted and checked for anaphylaxis.",
          "correct": true
        },
        {
          "label": "C",
          "text": "There is 50% absorption from 325 mg of ferrous sulfate via oral route.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Parenteral iron is the preferred treatment due to adverse effects of oral iron.",
          "correct": false
        }
      ],
      "correct_answer": "B. Before administering parenteral iron, the dose should be diluted and checked for anaphylaxis.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. Before administering parenteral iron, the dose should be diluted and checked for anaphylaxis.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A: Oral iron therapy typically continues until hemoglobin and hematocrit are normalized and should proceed for several months afterward to replenish iron stores. Discontinuation solely due to gastric side effects is not routine practice.</li><li>\u2022 Option A:</li><li>\u2022 Oral iron</li><li>\u2022 continues until hemoglobin and hematocrit are normalized</li><li>\u2022 several</li><li>\u2022 months afterward</li><li>\u2022 replenish iron stores.</li><li>\u2022 Discontinuation</li><li>\u2022 gastric side effects</li><li>\u2022 not routine practice.</li><li>\u2022 Option C: Absorption of oral ferrous sulfate is not as high as 50%; it is usually around 10-20%, and it is influenced by various factors like dietary components and patient\u2019s iron status.</li><li>\u2022 Option C:</li><li>\u2022 Absorption of oral ferrous sulfate</li><li>\u2022 not</li><li>\u2022 50%;</li><li>\u2022 usually</li><li>\u2022 10-20%,</li><li>\u2022 dietary components and patient\u2019s iron status.</li><li>\u2022 Option D: Oral iron is the preferred initial treatment for iron deficiency anemia due to convenience, cost-effectiveness , and generally good tolerability. Parenteral iron is reserved for specific circumstances.</li><li>\u2022 Option D:</li><li>\u2022 Oral iron</li><li>\u2022 initial treatment for iron deficiency anemia</li><li>\u2022 convenience, cost-effectiveness</li><li>\u2022 good tolerability. Parenteral iron</li><li>\u2022 reserved</li><li>\u2022 specific circumstances.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 When using parenteral iron for iron deficiency anemia, a test dose is necessary to monitor for anaphylaxis . Oral iron remains the first-line treatment , with continuation after normalization of hematocrit to replenish iron stores , while parenteral iron is used under specific conditions.</li><li>\u2022 parenteral iron</li><li>\u2022 iron deficiency anemia,</li><li>\u2022 test</li><li>\u2022 monitor for anaphylaxis</li><li>\u2022 Oral iron</li><li>\u2022 first-line treatment</li><li>\u2022 continuation after normalization of hematocrit</li><li>\u2022 replenish iron stores</li><li>\u2022 parenteral iron</li><li>\u2022 under specific conditions.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d13481d5",
      "audio": ""
    },
    {
      "text": "Which of the following is an antifibrinolytic agent?",
      "options": [
        {
          "label": "A",
          "text": "Dabigatran",
          "correct": false
        },
        {
          "label": "B",
          "text": "Protamine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Alteplase",
          "correct": false
        },
        {
          "label": "D",
          "text": "Epsilon aminocaproic acid",
          "correct": true
        }
      ],
      "correct_answer": "D. Epsilon aminocaproic acid",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D. Epsilon aminocaproic acid</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A: Dabigatran is a direct thrombin inhibitor that prevents the formation of blood clots by inhibiting the activity of thrombin, a key enzyme in the clotting process.</li><li>\u2022 Option A:</li><li>\u2022 Dabigatran</li><li>\u2022 direct thrombin inhibitor</li><li>\u2022 prevents</li><li>\u2022 blood clots</li><li>\u2022 inhibiting</li><li>\u2022 activity of thrombin,</li><li>\u2022 Option B: Protamine is a medication used to reverse the effects of heparin . Protamine works by binding to heparin , neutralizing its anticoagulant effects.</li><li>\u2022 Option B:</li><li>\u2022 Protamine</li><li>\u2022 reverse the effects of heparin</li><li>\u2022 binding to heparin</li><li>\u2022 neutralizing its</li><li>\u2022 anticoagulant effects.</li><li>\u2022 Option C: Alteplase is a thrombolytic agent that works by converting plasminogen to plasmin, which breaks down fibrin clots . It is used in cases of acute MI and stroke.</li><li>\u2022 Option C:</li><li>\u2022 Alteplase</li><li>\u2022 thrombolytic agent</li><li>\u2022 converting plasminogen to plasmin,</li><li>\u2022 breaks down fibrin clots</li><li>\u2022 cases of acute MI and stroke.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Epsilon aminocaproic acid and tranexamic acid are antifibrinolytic agents that inhibit the conversion of plasminogen to plasmin, preventing the breakdown of fibrin clots.</li><li>\u2022 Epsilon aminocaproic acid</li><li>\u2022 tranexamic acid</li><li>\u2022 antifibrinolytic agents</li><li>\u2022 inhibit the conversion of plasminogen to plasmin, preventing the breakdown of fibrin clots.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a10993e4",
      "audio": ""
    },
    {
      "text": "Which of the following drugs is commonly used in treatment for cancer associated thromboembolism?",
      "options": [
        {
          "label": "A",
          "text": "Low molecular weight heparin",
          "correct": true
        },
        {
          "label": "B",
          "text": "Antithrombin III inhibitors",
          "correct": false
        },
        {
          "label": "C",
          "text": "Direct Xa inhibitors",
          "correct": false
        },
        {
          "label": "D",
          "text": "Warfarin",
          "correct": false
        }
      ],
      "correct_answer": "A. Low molecular weight heparin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. Low molecular weight heparin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B: Incorrect . Antithrombin III inhibitors aren't typically used in the treatment of thromboembolism; in fact, antithrombin is a natural inhibitor of coagulation factors , and heparins enhance its activity.</li><li>\u2022 Option B:</li><li>\u2022 Incorrect</li><li>\u2022 Antithrombin III inhibitors aren't</li><li>\u2022 thromboembolism;</li><li>\u2022 antithrombin</li><li>\u2022 natural inhibitor of coagulation factors</li><li>\u2022 heparins enhance its activity.</li><li>\u2022 Option C: Incorrect. While direct Xa inhibitors are used in the treatment of thromboembolism , LMWH remains the standard treatment for cancer-associated thrombosis.</li><li>\u2022 Option C:</li><li>\u2022 Incorrect.</li><li>\u2022 direct Xa inhibitors</li><li>\u2022 thromboembolism</li><li>\u2022 LMWH</li><li>\u2022 standard treatment</li><li>\u2022 cancer-associated thrombosis.</li><li>\u2022 Option D: Incorrect . Warfarin is used less frequently in the cancer population for thromboembolism due to the need for regular monitoring and dose adjustments , and it has been surpassed by LMWH in terms of efficacy and safety.</li><li>\u2022 Option D:</li><li>\u2022 Incorrect</li><li>\u2022 Warfarin</li><li>\u2022 less frequently in the cancer</li><li>\u2022 thromboembolism</li><li>\u2022 regular monitoring and dose adjustments</li><li>\u2022 has been surpassed by LMWH</li><li>\u2022 efficacy and safety.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Low molecular weight heparin is the preferred agent for treating cancer-associated thromboembolism due to its efficacy and safety profile, especially compared to warfarin.</li><li>\u2022 Low molecular weight heparin</li><li>\u2022 treating cancer-associated thromboembolism</li><li>\u2022 its efficacy and safety</li><li>\u2022 profile,</li><li>\u2022 compared to warfarin.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "cd5aa7b9",
      "audio": ""
    },
    {
      "text": "Which of the following statements about prasugrel is true as compared to clopidogrel?",
      "options": [
        {
          "label": "A",
          "text": "It is slower acting than clopidogrel.",
          "correct": false
        },
        {
          "label": "B",
          "text": "It is contraindicated in stroke.",
          "correct": true
        },
        {
          "label": "C",
          "text": "It is a reversible antagonist of ADP receptors.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Decrease the risk of bleeding.",
          "correct": false
        }
      ],
      "correct_answer": "B. It is contraindicated in stroke.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. It is contraindicated in stroke.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. It is slower acting than clopidogrel: Prasugrel is actually converted to its active metabolite more rapidly than clopidogrel, leading to more potent and rapid platelet inhibition . Therefore, this statement is incorrect.</li><li>\u2022 Option A.</li><li>\u2022 slower acting</li><li>\u2022 Prasugrel</li><li>\u2022 converted to its active metabolite</li><li>\u2022 more rapidly</li><li>\u2022 more potent</li><li>\u2022 rapid platelet inhibition</li><li>\u2022 incorrect.</li><li>\u2022 Option C. It is a reversible antagonist of ADP receptors: Prasugrel, like clopidogrel , is an irreversible antagonist of ADP receptors on platelets . It forms a covalent bond with the P2Y12 receptor, resulting in irreversible inhibition of platelet aggregation. Thus, this statement is incorrect.</li><li>\u2022 Option C.</li><li>\u2022 reversible antagonist</li><li>\u2022 ADP receptors:</li><li>\u2022 Prasugrel, like clopidogrel</li><li>\u2022 irreversible antagonist</li><li>\u2022 ADP receptors on</li><li>\u2022 platelets</li><li>\u2022 covalent bond with the P2Y12 receptor,</li><li>\u2022 irreversible inhibition</li><li>\u2022 platelet aggregation.</li><li>\u2022 incorrect.</li><li>\u2022 Option D. Decrease the risk of bleeding : Prasugrel has been associated with an increased risk of bleeding compared to clopidogrel, especially in certain patient populations . Therefore, this statement is incorrect.</li><li>\u2022 Option D.</li><li>\u2022 Decrease</li><li>\u2022 risk of bleeding</li><li>\u2022 Prasugrel</li><li>\u2022 increased risk of bleeding</li><li>\u2022 clopidogrel,</li><li>\u2022 certain patient populations</li><li>\u2022 incorrect.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Prasugrel is contraindicated in patients with a history of stroke or transient ischemic attack (TIA) due to an increased risk of bleeding.</li><li>\u2022 Prasugrel</li><li>\u2022 contraindicated in patients</li><li>\u2022 history of stroke or transient ischemic attack (TIA)</li><li>\u2022 increased risk of bleeding.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ef11b90d",
      "audio": ""
    },
    {
      "text": "A 48-year-old male with a diagnosis of chronic idiopathic thrombocytopenic purpura (ITP) presents with easy bruising and a platelet count of 25,000/\u00b5L. He has previously been treated with corticosteroids with temporary improvement in platelet counts. The physician considers adding Eltrombopag for treatment of this patient. What is the mechanism of action of this drug?",
      "options": [
        {
          "label": "A",
          "text": "Thrombopoietin agonist",
          "correct": true
        },
        {
          "label": "B",
          "text": "Thrombopoietin antagonist",
          "correct": false
        },
        {
          "label": "C",
          "text": "Spleen tyrosine kinase inhibitor",
          "correct": false
        },
        {
          "label": "D",
          "text": "Recombinant IL-11",
          "correct": false
        }
      ],
      "correct_answer": "A. Thrombopoietin agonist",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. Thrombopoietin agonist</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Thrombopoietin antagonist: This would be incorrect because an antagonist would block the effect of thrombopoietin , which would not help to increase platelet counts in a patient with ITP.</li><li>\u2022 Option B. Thrombopoietin antagonist:</li><li>\u2022 incorrect</li><li>\u2022 antagonist</li><li>\u2022 block</li><li>\u2022 thrombopoietin</li><li>\u2022 would not</li><li>\u2022 increase platelet counts</li><li>\u2022 Option C. Spleen tyrosine kinase inhibitor: fostamatinib is an example of a spleen tyrosine kinase (Syk) inhibitor, which has a different mechanism of action . Fostamatinib is used in the treatment of ITP by inhibiting the Syk enzyme , leading to a reduction in the immune-mediated destruction of platelets. It targets the signalling pathways in immune cells that are involved in the pathogenesis of autoimmune diseases and has been indicated for adult patients with chronic ITP who have not responded adequately to other therapies. Patients on fostamatinib are monitored for side effects such as hypertension and liver function abnormalities . Spleen tyrosine kinase inhibitors work on different pathways , typically related to the immune response, and are not used to increase platelet production.</li><li>\u2022 Option C. Spleen tyrosine kinase inhibitor:</li><li>\u2022 fostamatinib</li><li>\u2022 spleen tyrosine kinase (Syk) inhibitor,</li><li>\u2022 mechanism of action</li><li>\u2022 Fostamatinib</li><li>\u2022 used</li><li>\u2022 ITP by inhibiting the Syk enzyme</li><li>\u2022 reduction in</li><li>\u2022 immune-mediated destruction of platelets.</li><li>\u2022 targets</li><li>\u2022 signalling pathways</li><li>\u2022 immune cells</li><li>\u2022 autoimmune diseases</li><li>\u2022 adult patients with chronic ITP</li><li>\u2022 not</li><li>\u2022 adequately</li><li>\u2022 fostamatinib</li><li>\u2022 monitored for side effects</li><li>\u2022 hypertension and liver function</li><li>\u2022 abnormalities</li><li>\u2022 Spleen tyrosine kinase inhibitors</li><li>\u2022 different pathways</li><li>\u2022 immune response,</li><li>\u2022 are not</li><li>\u2022 increase platelet production.</li><li>\u2022 Option D. Recombinant IL-11: This option is incorrect because eltrombopag is not a form of recombinant interleukin-11 , which is another cytokine used in different clinical contexts.</li><li>\u2022 Option D. Recombinant IL-11:</li><li>\u2022 incorrect</li><li>\u2022 eltrombopag</li><li>\u2022 not</li><li>\u2022 recombinant interleukin-11</li><li>\u2022 cytokine</li><li>\u2022 Recombinant IL-11 , known as oprelvekin , is used to treat thrombocytopenia, but it is not the drug in question.</li><li>\u2022 Recombinant IL-11</li><li>\u2022 oprelvekin</li><li>\u2022 thrombocytopenia,</li><li>\u2022 not</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational objective is to recognize the mechanism of action of eltrombopag as a thrombopoietin receptor agonist , which is used to treat thrombocytopenia in conditions such as chronic ITP by stimulating platelet production in the bone marrow.</li><li>\u27a4 recognize the mechanism of action of eltrombopag</li><li>\u27a4 thrombopoietin receptor agonist</li><li>\u27a4 used to treat thrombocytopenia</li><li>\u27a4 chronic ITP</li><li>\u27a4 stimulating platelet production</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "99352c4e",
      "audio": ""
    },
    {
      "text": "A 36-week pregnant female was taking warfarin for prosthetic heart valves and has INR value of 3. Next step in the management is?",
      "options": [
        {
          "label": "A",
          "text": "Stop warfarin and start heparin.",
          "correct": true
        },
        {
          "label": "B",
          "text": "Stop warfarin and start heparin plus aspirin.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Continue warfarin and add heparin.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Switch to aspirin.",
          "correct": false
        }
      ],
      "correct_answer": "A. Stop warfarin and start heparin.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. Stop warfarin and start heparin.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Stop warfarin and start heparin plus aspirin: Aspirin is an antiplatelet agent and is not typically required in the context of prosthetic heart valve management during pregnancy. Its addition could increase the risk of bleeding without providing clear additional benefit in this setting.</li><li>\u2022 Option B. Stop warfarin and start heparin plus aspirin:</li><li>\u2022 Aspirin</li><li>\u2022 antiplatelet agent</li><li>\u2022 not</li><li>\u2022 prosthetic heart valve</li><li>\u2022 increase the risk of bleeding without</li><li>\u2022 additional benefit</li><li>\u2022 Option C. Continue warfarin and add heparin: Continuing warfarin is not recommended close to delivery due to the risks mentioned above. The goal is to switch to heparin solely.</li><li>\u2022 Option C. Continue warfarin and add heparin:</li><li>\u2022 not recommended close to delivery</li><li>\u2022 risks</li><li>\u2022 goal is</li><li>\u2022 switch to heparin</li><li>\u2022 Option D. Switch to aspirin: Aspirin alone is insufficient for the management of thromboembolic risk in patients with prosthetic heart valves. Anticoagulation with heparin is necessary.</li><li>\u2022 Option D. Switch to aspirin:</li><li>\u2022 Aspirin</li><li>\u2022 insufficient</li><li>\u2022 thromboembolic risk in patients</li><li>\u2022 prosthetic</li><li>\u2022 heart valves. Anticoagulation with heparin is necessary.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational objective is to recognize the importance of transitioning from warfarin to heparin in pregnant patients with mechanical heart valves as they approach delivery. Warfarin is contraindicated close to delivery due to the risk of fetal hemorrhage, and heparin is the preferred anticoagulant because it does not cross the placenta . This transition minimizes the risk of thromboembolism associated with the prosthetic valve and reduces the potential for bleeding complications during labor and delivery.</li><li>\u27a4 importance of transitioning from warfarin to heparin in pregnant patients</li><li>\u27a4 mechanical heart valves</li><li>\u27a4 delivery. Warfarin is contraindicated</li><li>\u27a4 risk of fetal hemorrhage,</li><li>\u27a4 heparin</li><li>\u27a4 anticoagulant</li><li>\u27a4 does not cross the placenta</li><li>\u27a4 minimizes the risk of</li><li>\u27a4 thromboembolism</li><li>\u27a4 prosthetic valve</li><li>\u27a4 reduces</li><li>\u27a4 bleeding complications</li><li>\u27a4 labor and</li><li>\u27a4 delivery.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "aa5e8e09",
      "audio": ""
    },
    {
      "text": "Which of the following statements is NOT a characteristic feature of treatment of iron deficiency anaemia with oral iron supplements?",
      "options": [
        {
          "label": "A",
          "text": "If 200-300 mg elemental iron is consumed, about 50 mg is absorbed.",
          "correct": false
        },
        {
          "label": "B",
          "text": "The proportion of iron absorbed reduces as haemoglobin improves.",
          "correct": false
        },
        {
          "label": "C",
          "text": "The reticulocyte count should begin to increase in two weeks and peak in four weeks - this suggests a good response to treatment.",
          "correct": false
        },
        {
          "label": "D",
          "text": "The treatment should be discontinued immediately once haemoglobin normalizes to prevent side effects of iron.",
          "correct": true
        }
      ],
      "correct_answer": "D. The treatment should be discontinued immediately once haemoglobin normalizes to prevent side effects of iron.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D. The treatment should not be discontinued immediately once haemoglobin normalizes to prevent recurrence of iron deficiency anaemia.</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 When treating iron deficiency anemia with oral iron supplements , it is essential to understand that the body absorbs about 10-20% of the elemental iron from these supplements , meaning that from a dose of 200-300 mg, around 20-60 mg is absorbed . As hemoglobin levels improve, the efficiency of iron absorption decreases due to the body's natural regulatory mechanisms to prevent iron overload. An effective response to treatment is indicated by an increase in reticulocyte count , typically observed within 2 weeks and peaking at 4 weeks. Importantly, iron supplementation should continue for 3-6 months after hemoglobin normalization to ensure complete replenishment of iron stores and prevent the recurrence of anemia, highlighting that stopping treatment immediately after normalization is incorrect. Understanding these principles helps in the effective management of iron deficiency anemia and in preventing its recurrence.</li><li>\u27a4 iron deficiency anemia</li><li>\u27a4 oral iron supplements</li><li>\u27a4 body absorbs</li><li>\u27a4 10-20%</li><li>\u27a4 elemental iron</li><li>\u27a4 supplements</li><li>\u27a4 dose of 200-300 mg,</li><li>\u27a4 20-60</li><li>\u27a4 mg</li><li>\u27a4 absorbed</li><li>\u27a4 hemoglobin levels improve,</li><li>\u27a4 efficiency of iron absorption decreases</li><li>\u27a4 natural regulatory mechanisms</li><li>\u27a4 prevent iron overload.</li><li>\u27a4 increase in reticulocyte count</li><li>\u27a4 within 2 weeks</li><li>\u27a4 peaking at 4 weeks.</li><li>\u27a4 iron</li><li>\u27a4 supplementation</li><li>\u27a4 continue for 3-6 months</li><li>\u27a4 hemoglobin normalization</li><li>\u27a4 complete replenishment</li><li>\u27a4 iron stores</li><li>\u27a4 prevent</li><li>\u27a4 recurrence of anemia,</li><li>\u27a4 stopping</li><li>\u27a4 immediately</li><li>\u27a4 after normalization</li><li>\u27a4 incorrect.</li><li>\u27a4 helps</li><li>\u27a4 effective management of iron deficiency</li><li>\u27a4 anemia</li><li>\u27a4 preventing its recurrence.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7d0593a4",
      "audio": ""
    },
    {
      "text": "A healthy volunteer was taken for a blood donation. A history was taken from the volunteer before the experiment regarding exposure of NSAIDs, which he specifically denied. But on testing, the bleeding time was found to be increased. All the following can be responsible for increase in bleeding time in this person EXCEPT",
      "options": [
        {
          "label": "A",
          "text": "Clopidogrel",
          "correct": false
        },
        {
          "label": "B",
          "text": "Cephalosporins",
          "correct": false
        },
        {
          "label": "C",
          "text": "Anti-depressants",
          "correct": false
        },
        {
          "label": "D",
          "text": "Multivitamins",
          "correct": true
        }
      ],
      "correct_answer": "D. Multivitamins",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/picture1_hSfcgav.jpg"
      ],
      "explanation": "<p><strong>Ans. D. Multivitamins</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Clopidogrel: Clopidogrel is an antiplatelet drug that inhibits the P2Y12 ADP receptor on platelets, preventing platelet aggregation and thus can increase bleeding time . It is used to reduce the risk of heart disease and stroke in those at high risk.</li><li>\u2022 Option A. Clopidogrel:</li><li>\u2022 antiplatelet drug that inhibits the P2Y12 ADP receptor on platelets, preventing platelet</li><li>\u2022 aggregation</li><li>\u2022 increase bleeding time</li><li>\u2022 reduce the risk of heart disease</li><li>\u2022 stroke</li><li>\u2022 Option B. Cephalosporins: Certain cephalosporins, especially those with a methylthiotetrazole (MTT) side chain (like cefotetan and cefoperazone ), can interfere with vitamin K metabolism or have a direct effect on platelet function , leading to an increased risk of bleeding . This makes cephalosporins a plausible cause for an increased bleeding time in individuals without apparent exposure to NSAIDs.</li><li>\u2022 Option B. Cephalosporins:</li><li>\u2022 cephalosporins,</li><li>\u2022 methylthiotetrazole (MTT)</li><li>\u2022 cefotetan</li><li>\u2022 cefoperazone</li><li>\u2022 interfere with vitamin K metabolism</li><li>\u2022 direct effect on platelet function</li><li>\u2022 increased risk of</li><li>\u2022 bleeding</li><li>\u2022 cephalosporins a plausible</li><li>\u2022 increased bleeding time in individuals</li><li>\u2022 without</li><li>\u2022 NSAIDs.</li><li>\u2022 Option C. Anti-depressants: Some antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs) , can increase bleeding time . SSRIs increase serotonin levels in the central nervous system but can also lead to a reduction in serotonin storage within platelets , which plays a role in platelet aggregation. This effect can subtly increase bleeding time , making antidepressants a possible cause for the observation.</li><li>\u2022 Option C. Anti-depressants:</li><li>\u2022 selective serotonin reuptake inhibitors (SSRIs)</li><li>\u2022 increase</li><li>\u2022 bleeding time</li><li>\u2022 increase serotonin levels</li><li>\u2022 lead to a reduction in serotonin storage</li><li>\u2022 within platelets</li><li>\u2022 platelet aggregation.</li><li>\u2022 increase bleeding time</li><li>\u2022 antidepressants</li><li>\u2022 cause for the observation.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational objective is to recognize substances that can affect bleeding time , with a specific focus on understanding that c ommon multivitamins do not typically cause an increase in bleeding time.</li><li>\u27a4 recognize substances</li><li>\u27a4 affect bleeding time</li><li>\u27a4 specific focus</li><li>\u27a4 ommon multivitamins</li><li>\u27a4 do not</li><li>\u27a4 increase in bleeding time.</li><li>\u27a4 Important Drugs that can increasing bleeding time</li><li>\u27a4 Important Drugs that can increasing bleeding time</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ffa8d430",
      "audio": ""
    },
    {
      "text": "Platelet aggregation is blocked by aspirin due to its action on:",
      "options": [
        {
          "label": "A",
          "text": "Prostacyclin",
          "correct": false
        },
        {
          "label": "B",
          "text": "PGF 2\u03b1",
          "correct": false
        },
        {
          "label": "C",
          "text": "Thromboxane A2",
          "correct": true
        },
        {
          "label": "D",
          "text": "Phospholipase C",
          "correct": false
        }
      ],
      "correct_answer": "C. Thromboxane A2",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. Thromboxane A2</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A: Incorrect . Prostacyclin (PGI2) is an anti-aggregatory prostaglandin produced by endothelial cells , and aspirin actually helps to prevent thrombosis partly by not significantly affecting prostacyclin production.</li><li>\u2022 Option A:</li><li>\u2022 Incorrect</li><li>\u2022 Prostacyclin (PGI2)</li><li>\u2022 anti-aggregatory prostaglandin</li><li>\u2022 endothelial cells</li><li>\u2022 aspirin</li><li>\u2022 prevent thrombosis</li><li>\u2022 not</li><li>\u2022 prostacyclin production.</li><li>\u2022 Option B: Incorrect. PGF 2\u03b1 (Prostaglandin F2 alpha) is not a major target of aspirin in the context of antiplatelet therapy.</li><li>\u2022 Option B:</li><li>\u2022 Incorrect. PGF 2\u03b1 (Prostaglandin F2 alpha)</li><li>\u2022 not</li><li>\u2022 aspirin</li><li>\u2022 antiplatelet therapy.</li><li>\u2022 Option D: Incorrect. Phospholipase C is not inhibited by aspirin ; aspirin targets COX enzymes.</li><li>\u2022 Option D: Incorrect.</li><li>\u2022 Phospholipase C</li><li>\u2022 not</li><li>\u2022 aspirin</li><li>\u2022 targets COX enzymes.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Aspirin blocks platelet aggregation by inhibiting the production of thromboxane A2 through irreversible acetylation of the COX-1 enzyme in platelets , affecting their function for the remainder of their lifespan.</li><li>\u2022 Aspirin</li><li>\u2022 blocks platelet aggregation</li><li>\u2022 inhibiting the production of thromboxane A2</li><li>\u2022 irreversible acetylation of the COX-1</li><li>\u2022 enzyme in platelets</li><li>\u2022 function</li><li>\u2022 their lifespan.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "59cc8731",
      "audio": ""
    },
    {
      "text": "Warfarin embryopathy is due to the action of?",
      "options": [
        {
          "label": "A",
          "text": "Osteophysin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Osteotensin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Osteocalcin",
          "correct": true
        },
        {
          "label": "D",
          "text": "Osteogenin",
          "correct": false
        }
      ],
      "correct_answer": "C. Osteocalcin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. Osteocalcin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Osteophysin: There is no known substance called osteophysin . It does not play a role in warfarin embryopathy.</li><li>\u2022 Option A. Osteophysin:</li><li>\u2022 no</li><li>\u2022 osteophysin</li><li>\u2022 does not</li><li>\u2022 warfarin embryopathy.</li><li>\u2022 Option B. Osteotensin: Osteotensin is not associated with warfarin embryopathy. It is not a recognized factor involved in bone development or the effects of warfarin on fetal development.</li><li>\u2022 Option B. Osteotensin:</li><li>\u2022 Osteotensin</li><li>\u2022 not</li><li>\u2022 with warfarin embryopathy.</li><li>\u2022 not</li><li>\u2022 recognized factor</li><li>\u2022 bone</li><li>\u2022 development</li><li>\u2022 effects of warfarin</li><li>\u2022 fetal development.</li><li>\u2022 Option D. Osteogenin: Osteogenin, also known as bone morphogenetic protein-3 (BMP-3), is a protein involved in bone formation and development . However, it is not implicated in the mechanism of warfarin embryopathy.</li><li>\u2022 Option D. Osteogenin:</li><li>\u2022 Osteogenin,</li><li>\u2022 bone morphogenetic protein-3 (BMP-3),</li><li>\u2022 protein</li><li>\u2022 bone formation</li><li>\u2022 and development</li><li>\u2022 not</li><li>\u2022 mechanism of warfarin embryopathy.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Warfarin embryopathy results from the inhibition of vitamin K-dependent carboxylation of osteocalcin, a bone matrix protein essential for proper bone development during fetal life.</li><li>\u2022 Warfarin embryopathy</li><li>\u2022 inhibition of vitamin K-dependent carboxylation of osteocalcin,</li><li>\u2022 bone matrix protein</li><li>\u2022 proper bone development during fetal life.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6360b5f8",
      "audio": ""
    },
    {
      "text": "All are ADP inhibitors except:",
      "options": [
        {
          "label": "A",
          "text": "Ticlopidine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Tirofiban",
          "correct": true
        },
        {
          "label": "C",
          "text": "Clopidogrel",
          "correct": false
        },
        {
          "label": "D",
          "text": "Prasugrel",
          "correct": false
        }
      ],
      "correct_answer": "B. Tirofiban",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/picture7.jpg"
      ],
      "explanation": "<p><strong>Ans. B. Tirofiban</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Ticlopidine: Ticlopidine is an ADP receptor inhibitor that inhibits platelet aggregation by blocking the P2Y12 ADP recepto r on the platelet surface, making it less responsive to stimuli that cause aggregation.</li><li>\u2022 Option A. Ticlopidine:</li><li>\u2022 ADP receptor inhibitor</li><li>\u2022 inhibits platelet aggregation</li><li>\u2022 blocking the P2Y12 ADP recepto</li><li>\u2022 platelet surface,</li><li>\u2022 less responsive to stimuli</li><li>\u2022 aggregation.</li><li>\u2022 Option C. Clopidogrel: Clopidogrel is also an ADP receptor inhibitor , similar to ticlopidine, that works by irreversibly inhibiting the P2Y12 subtype of the ADP receptor on platelets, thus reducing platelet aggregation.</li><li>\u2022 Option C. Clopidogrel:</li><li>\u2022 Clopidogrel</li><li>\u2022 ADP receptor inhibitor</li><li>\u2022 irreversibly inhibiting</li><li>\u2022 P2Y12 subtype of the ADP receptor</li><li>\u2022 reducing platelet aggregation.</li><li>\u2022 Option D. Prasugrel: Prasugrel is a third example of an ADP receptor inhibitor. It is a prodrug that, once metabolized, inhibits the P2Y12 ADP receptor on platelets , leading to decreased platelet aggregation.</li><li>\u2022 Option D. Prasugrel:</li><li>\u2022 ADP receptor inhibitor.</li><li>\u2022 prodrug</li><li>\u2022 once metabolized,</li><li>\u2022 inhibits</li><li>\u2022 P2Y12 ADP receptor on platelets</li><li>\u2022 decreased platelet aggregation.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational objective is to identify the classification of antiplatelet drugs, specifically distinguishing ADP receptor inhibitors (ticlopidine, clopidogrel, and prasugrel) from other classes such as glycoprotein IIb/IIIa inhibitors (tirofiban).</li><li>\u27a4 identify the classification of antiplatelet drugs,</li><li>\u27a4 ADP receptor inhibitors</li><li>\u27a4 (ticlopidine, clopidogrel, and prasugrel)</li><li>\u27a4 other classes</li><li>\u27a4 glycoprotein IIb/IIIa inhibitors (tirofiban).</li><li>\u27a4 Antiplatelet Drugs</li><li>\u27a4 Antiplatelet Drugs</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "20e6b3e8",
      "audio": ""
    },
    {
      "text": "A 45-year-old patient was started on anticoagulant therapy for DVT. Few days after he presented to emergency with the features as shown in figure. Which could be the culprit drug?",
      "options": [
        {
          "label": "A",
          "text": "Warfarin",
          "correct": true
        },
        {
          "label": "B",
          "text": "Dabigatran",
          "correct": false
        },
        {
          "label": "C",
          "text": "Rivaroxaban",
          "correct": false
        },
        {
          "label": "D",
          "text": "Heparin",
          "correct": false
        }
      ],
      "correct_answer": "A. Warfarin",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/picture9.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. Warfarin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Dabigatran: Dabigatran is a direct thrombin inhibitor and is not associated with dermal vascular necrosis . It does not affect protein C levels or lead to hypercoagulable states like warfarin.</li><li>\u2022 Option B. Dabigatran:</li><li>\u2022 direct thrombin inhibitor</li><li>\u2022 not associated with dermal vascular necrosis</li><li>\u2022 does not</li><li>\u2022 affect protein C levels</li><li>\u2022 hypercoagulable states</li><li>\u2022 warfarin.</li><li>\u2022 Option C. Rivaroxaban: Rivaroxaban is a factor Xa inhibitor and is not associated with dermal vascular necrosis . Like dabigatran, it does not affect protein C levels or lead to hypercoagulable states like warfarin.</li><li>\u2022 Option C. Rivaroxaban:</li><li>\u2022 factor Xa inhibitor</li><li>\u2022 not</li><li>\u2022 dermal vascular necrosis</li><li>\u2022 does not</li><li>\u2022 protein C levels</li><li>\u2022 lead to hypercoagulable states</li><li>\u2022 warfarin.</li><li>\u2022 Option D. Heparin: Heparin is a different class of anticoagulant and is not associated with dermal vascular necrosis . It works by enhancing the activity of antithrombin III and inhibiting the coagulation cascade at multiple points.</li><li>\u2022 Option D. Heparin:</li><li>\u2022 Heparin</li><li>\u2022 anticoagulant</li><li>\u2022 not</li><li>\u2022 dermal vascular necrosis</li><li>\u2022 enhancing the activity of antithrombin III</li><li>\u2022 inhibiting</li><li>\u2022 coagulation cascade at multiple points.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Warfarin-induced dermal vascular necrosis, also known as 'purple toe syndrome,' is a rare complication of warfarin therapy seen in patients with genetic protein C deficiency . Prompt recognition and management are essential to prevent further complications.</li><li>\u2022 Warfarin-induced dermal vascular necrosis,</li><li>\u2022 'purple toe syndrome,'</li><li>\u2022 rare</li><li>\u2022 warfarin therapy</li><li>\u2022 genetic protein C deficiency</li><li>\u2022 Prompt recognition and management</li><li>\u2022 essential to prevent further complications.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0c9a0c48",
      "audio": ""
    },
    {
      "text": "A 72-year-old male with a history of non-valvular atrial fibrillation is brought to the emergency department following a minor car accident. He is currently taking dabigatran for stroke prevention. On examination, he has a laceration on his forehead that is bleeding profusely, and his blood tests reveal a prolonged activated partial thromboplastin time (aPTT). Given the acute bleeding and his anticoagulation therapy, the emergency physician decides to administer a specific antidote to reverse the effects of dabigatran. Which of the following medications should be used?",
      "options": [
        {
          "label": "A",
          "text": "Protamine sulfate",
          "correct": false
        },
        {
          "label": "B",
          "text": "Vitamin K",
          "correct": false
        },
        {
          "label": "C",
          "text": "Andexanet \u03b1",
          "correct": false
        },
        {
          "label": "D",
          "text": "Idarucizumab",
          "correct": true
        }
      ],
      "correct_answer": "D. Idarucizumab",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/picture13.jpg"
      ],
      "explanation": "<p><strong>Ans. D. Idarucizumab</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Protamine sulfate: Protamine sulfate is used to reverse the effects of heparin, not direct thrombin inhibitors like dabigatran.</li><li>\u2022 Option A. Protamine sulfate:</li><li>\u2022 reverse the effects of heparin,</li><li>\u2022 Option B. Vitamin K: Vitamin K is used to reverse the anticoagulant effects of warfarin, a vitamin K antagonist . It is not effective against the anticoagulant effects of dabigatran.</li><li>\u2022 Option B. Vitamin K:</li><li>\u2022 reverse the anticoagulant effects of warfarin,</li><li>\u2022 vitamin K antagonist</li><li>\u2022 not</li><li>\u2022 anticoagulant effects of dabigatran.</li><li>\u2022 Option C. Andexanet \u03b1: Andexanet alfa is an antidote for the reversal of the anticoagulant effects of Factor Xa inhibitors , not direct thrombin inhibitors.</li><li>\u2022 Option C. Andexanet \u03b1:</li><li>\u2022 antidote</li><li>\u2022 reversal of the anticoagulant effects of Factor Xa inhibitors</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational objective is to know the antidotes of different anti-coagulants particularly idarucizumab as the specific reversal agent for dabigatran , a direct thrombin inhibitor.</li><li>\u27a4 antidotes of different anti-coagulants</li><li>\u27a4 idarucizumab</li><li>\u27a4 reversal</li><li>\u27a4 agent for dabigatran</li><li>\u27a4 direct thrombin inhibitor.</li><li>\u27a4 ANTIDOTES OF ANTI-COAGULANTS</li><li>\u27a4 ANTIDOTES OF ANTI-COAGULANTS</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "654fecd8",
      "audio": ""
    },
    {
      "text": "Which of the following statements is true regarding the warfarin group of oral anticoagulants?",
      "options": [
        {
          "label": "A",
          "text": "These interfere with the synthesis of vitamin K dependent clotting factors.",
          "correct": false
        },
        {
          "label": "B",
          "text": "These can produce anticoagulant effect both in vivo and in vitro.",
          "correct": false
        },
        {
          "label": "C",
          "text": "These can produce bleeding like hematuria and cerebral hemorrhage.",
          "correct": true
        },
        {
          "label": "D",
          "text": "Their action starts immediately, so are useful for initiation of therapy in deep vein thrombosis.",
          "correct": false
        }
      ],
      "correct_answer": "C. These can produce bleeding like hematuria and cerebral hemorrhage.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. These can produce bleeding like hematuria and cerebral hemorrhage</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. These interfere with the synthesis of vitamin K dependent clotting factors.</li><li>\u2022 Option A.</li><li>\u2022 These interfere with the synthesis of vitamin K dependent clotting factors.</li><li>\u2022 This statement is incorrect. Warfarin and other drugs in its class inhibit the activation of vitamin K-dependent clotting factors rather than interfering with their synthesis . These factors include II, VII, IX, and X.</li><li>\u2022 This statement is incorrect. Warfarin and other drugs in its class inhibit the activation of vitamin K-dependent clotting factors rather than interfering with their synthesis . These factors include II, VII, IX, and X.</li><li>\u2022 incorrect.</li><li>\u2022 class inhibit the activation of vitamin K-dependent clotting</li><li>\u2022 factors</li><li>\u2022 their synthesis</li><li>\u2022 II, VII, IX, and X.</li><li>\u2022 Option B. These can produce anticoagulant effect both in vivo and in vitro.</li><li>\u2022 Option B.</li><li>\u2022 These can produce anticoagulant effect both in vivo and in vitro.</li><li>\u2022 This statement is incorrect . Warfarin and similar drugs primarily exert their anticoagulant effects in vivo , within the body . They do not directly affect clotting factors outside of the body (in vitro).</li><li>\u2022 This statement is incorrect . Warfarin and similar drugs primarily exert their anticoagulant effects in vivo , within the body . They do not directly affect clotting factors outside of the body (in vitro).</li><li>\u2022 incorrect</li><li>\u2022 anticoagulant effects in vivo</li><li>\u2022 within the</li><li>\u2022 body</li><li>\u2022 do not</li><li>\u2022 clotting factors outside of the body (in vitro).</li><li>\u2022 Option C. These can produce bleeding like hematuria and cerebral hemorrhage.</li><li>\u2022 Option C.</li><li>\u2022 These can produce bleeding like hematuria and cerebral hemorrhage.</li><li>\u2022 This statement is true . Bleeding, including hematuria (blood in the urine) and cerebral hemorrhage (bleeding in the brain) , is a common adverse effect of warfarin and other oral anticoagulants . This risk is particularly relevant when using these medications due to their anticoagulant effects.</li><li>\u2022 This statement is true . Bleeding, including hematuria (blood in the urine) and cerebral hemorrhage (bleeding in the brain) , is a common adverse effect of warfarin and other oral anticoagulants . This risk is particularly relevant when using these medications due to their anticoagulant effects.</li><li>\u2022 true</li><li>\u2022 hematuria (blood in the urine)</li><li>\u2022 cerebral hemorrhage (bleeding in the</li><li>\u2022 brain)</li><li>\u2022 common adverse effect</li><li>\u2022 warfarin and other oral anticoagulants</li><li>\u2022 risk</li><li>\u2022 using</li><li>\u2022 medications</li><li>\u2022 anticoagulant effects.</li><li>\u2022 Option D. Their action starts immediately, so are useful for initiation of therapy in deep vein thrombosis.</li><li>\u2022 Option D.</li><li>\u2022 Their action starts immediately, so are useful for initiation of therapy in deep vein thrombosis.</li><li>\u2022 This statement is incorrect . The action of warfarin and similar drugs is delayed , typically taking 1-3 days to produce a therapeutic effect. Therefore, they are not useful for the immediate initiation of therapy in conditions like deep vein thrombosis , where more rapid anticoagulation is required.</li><li>\u2022 This statement is incorrect . The action of warfarin and similar drugs is delayed , typically taking 1-3 days to produce a therapeutic effect. Therefore, they are not useful for the immediate initiation of therapy in conditions like deep vein thrombosis , where more rapid anticoagulation is required.</li><li>\u2022 incorrect</li><li>\u2022 warfarin and similar drugs is delayed</li><li>\u2022 1-3 days</li><li>\u2022 therapeutic effect.</li><li>\u2022 not useful for the immediate initiation of therapy</li><li>\u2022 deep vein</li><li>\u2022 thrombosis</li><li>\u2022 more rapid anticoagulation</li><li>\u2022 required.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Warfarin and similar oral anticoagulants primarily exert their effects in vivo, can lead to bleeding complications such as hematuria and cerebral hemorrhage , and have a delayed onset of action, making them unsuitable for immediate therapy initiation in conditions like deep vein thrombosis.</li><li>\u2022 Warfarin and similar oral anticoagulants</li><li>\u2022 effects in vivo,</li><li>\u2022 bleeding complications</li><li>\u2022 hematuria</li><li>\u2022 cerebral hemorrhage</li><li>\u2022 delayed onset of action,</li><li>\u2022 unsuitable for immediate therapy</li><li>\u2022 deep vein thrombosis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2840c06c",
      "audio": ""
    },
    {
      "text": "Which of the following drugs reversibly binds the site labelled as B in the given figure?",
      "options": [
        {
          "label": "A",
          "text": "Clopidogrel",
          "correct": false
        },
        {
          "label": "B",
          "text": "Prasugrel",
          "correct": false
        },
        {
          "label": "C",
          "text": "Ticagrelor",
          "correct": true
        },
        {
          "label": "D",
          "text": "Ticlopidine",
          "correct": false
        }
      ],
      "correct_answer": "C. Ticagrelor",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/picture14.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. Ticagrelor</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Clopidogrel: Clopidogrel irreversibly binds to the P2Y12 receptor , preventing ADP from binding and thus inhibiting platelet activation and aggregation.</li><li>\u2022 Option A. Clopidogrel:</li><li>\u2022 irreversibly binds to the P2Y12 receptor</li><li>\u2022 preventing ADP from binding</li><li>\u2022 inhibiting</li><li>\u2022 platelet activation and aggregation.</li><li>\u2022 Option B. Prasugrel: Prasugrel is another thienopyridine that irreversibly inhibits the P2Y12 receptor, similar to clopidogrel.</li><li>\u2022 Option B. Prasugrel:</li><li>\u2022 thienopyridine</li><li>\u2022 irreversibly inhibits the P2Y12 receptor,</li><li>\u2022 Option D. Ticlopidine: Ticlopidine was one of the first thienopyridine drugs to inhibit the P2Y12 receptor irreversibly. It is less commonly used now due to its side effect profile.</li><li>\u2022 Option D. Ticlopidine:</li><li>\u2022 first thienopyridine drugs to inhibit the P2Y12 receptor irreversibly.</li><li>\u2022 less</li><li>\u2022 commonly used</li><li>\u2022 its side effect profile.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational objective is to understand the mechanism of action of P2Y12 inhibitors and to differentiate between reversible and irreversible inhibition of this receptor . Ticagrelor's ability to reversibly bind the P2Y12 receptor on platelets distinguishes it from other thienopyridine drugs, which bind irreversibly, and has clinical implications for the management of patients requiring antiplatelet therapy.</li><li>\u27a4 mechanism of action of P2Y12 inhibitors</li><li>\u27a4 differentiate between reversible</li><li>\u27a4 irreversible inhibition of this receptor</li><li>\u27a4 Ticagrelor's ability</li><li>\u27a4 reversibly bind the P2Y12 receptor</li><li>\u27a4 platelets distinguishes</li><li>\u27a4 thienopyridine drugs,</li><li>\u27a4 bind irreversibly,</li><li>\u27a4 clinical implications</li><li>\u27a4 antiplatelet therapy.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9636edd3",
      "audio": ""
    },
    {
      "text": "For oral iron supplements used for iron deficiency anaemia, which of the following statements is correct?",
      "options": [
        {
          "label": "A",
          "text": "Tolerable dose will deliver 40 to 60 mg of iron per day.",
          "correct": true
        },
        {
          "label": "B",
          "text": "Mass of total salt is important in determining daily dose.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Treatment should be stopped as soon as normal haemoglobin level is reached.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Desired rate of haemoglobin improvement is 0.5 mg per day.",
          "correct": false
        }
      ],
      "correct_answer": "A. Tolerable dose will deliver 40 to 60 mg of iron per day.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. Tolerable dose will deliver 40 to 60 mg of iron per day.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B: It is the mass of elemental iron , rather than the mass of total salt , that is critical in determining the daily dose, because the percentage of elemental iron varies between different iron salts.</li><li>\u2022 Option B:</li><li>\u2022 mass of elemental iron</li><li>\u2022 mass of total salt</li><li>\u2022 daily dose,</li><li>\u2022 percentage of elemental iron</li><li>\u2022 different iron salts.</li><li>\u2022 Option C: Treatment with oral iron should not be stopped as soon as normal haemoglobin level is reached; it should continue for several months to replenish iron stores.</li><li>\u2022 Option C:</li><li>\u2022 Treatment</li><li>\u2022 oral iron</li><li>\u2022 not be stopped</li><li>\u2022 normal haemoglobin level is reached;</li><li>\u2022 several months to replenish iron stores.</li><li>\u2022 Option D: The desired rate of haemoglobin improvement is usually 0.5 to 1 g/dL per week, not per day.</li><li>\u2022 Option D:</li><li>\u2022 desired rate of haemoglobin improvement</li><li>\u2022 0.5 to 1 g/dL per week,</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 When treating iron deficiency anaemia, it's important to consider the amount of elemental iron in oral supplements and continue treatment beyond the normalization of haemoglobin to fully replenish iron stores.</li><li>\u2022 iron deficiency anaemia,</li><li>\u2022 amount of elemental iron in oral supplements</li><li>\u2022 continue</li><li>\u2022 treatment beyond the normalization of haemoglobin</li><li>\u2022 fully replenish iron stores.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "138c16ac",
      "audio": ""
    },
    {
      "text": "All the following drugs are Gp IIb/IIIa inhibitors except:",
      "options": [
        {
          "label": "A",
          "text": "Prasugrel",
          "correct": true
        },
        {
          "label": "B",
          "text": "Abciximab",
          "correct": false
        },
        {
          "label": "C",
          "text": "Tirofiban",
          "correct": false
        },
        {
          "label": "D",
          "text": "Eptifibatide",
          "correct": false
        }
      ],
      "correct_answer": "A. Prasugrel",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/picture5.jpg"
      ],
      "explanation": "<p><strong>Ans. A. Prasugrel</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Abciximab: Abciximab is a Gp IIb/IIIa inhibitor. It is a monoclonal antibody that binds to the Gp IIb/IIIa receptor on platelets , preventing the binding of fibrinogen and von Willebrand factor , which inhibits platelet aggregation. It is used in acute coronary syndrome and during percutaneous coronary interventions to prevent thrombosis.</li><li>\u2022 Option B. Abciximab:</li><li>\u2022 Gp IIb/IIIa inhibitor.</li><li>\u2022 monoclonal antibody</li><li>\u2022 binds</li><li>\u2022 Gp IIb/IIIa receptor</li><li>\u2022 platelets</li><li>\u2022 preventing the binding of fibrinogen</li><li>\u2022 von Willebrand factor</li><li>\u2022 inhibits platelet aggregation.</li><li>\u2022 used</li><li>\u2022 acute</li><li>\u2022 coronary syndrome</li><li>\u2022 percutaneous coronary interventions</li><li>\u2022 prevent thrombosis.</li><li>\u2022 Option C. Tirofiban: Tirofiban is a non-peptide antagonist of the Gp IIb/IIIa receptor, which inhibits platelet aggregation by preventing fibrinogen binding to the Gp IIb/IIIa receptor. It is used to prevent thrombotic cardiovascular events in patients with acute coronary syndrome.</li><li>\u2022 Option C. Tirofiban:</li><li>\u2022 non-peptide antagonist of the Gp IIb/IIIa receptor,</li><li>\u2022 inhibits platelet aggregation</li><li>\u2022 preventing fibrinogen binding to the Gp IIb/IIIa receptor.</li><li>\u2022 prevent thrombotic cardiovascular events</li><li>\u2022 acute coronary syndrome.</li><li>\u2022 Option D. Eptifibatide: Eptifibatide is a cyclic heptapeptide and a Gp IIb/IIIa inhibitor . It works by reversibly blocking the Gp IIb/IIIa receptor , thereby inhibiting platelet aggregation. It is used in the management of acute coronary syndrome and during percutaneous coronary interventions.</li><li>\u2022 Option D. Eptifibatide:</li><li>\u2022 cyclic heptapeptide and a Gp IIb/IIIa inhibitor</li><li>\u2022 reversibly blocking the Gp IIb/IIIa receptor</li><li>\u2022 inhibiting platelet aggregation.</li><li>\u2022 used</li><li>\u2022 acute coronary syndrome</li><li>\u2022 percutaneous coronary interventions.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational objective is to recognize the classification of antiplatelet agents , particularly distinguishing between Gp IIb/IIIa inhibitors (abciximab, tirofiban, and eptifibatide) and other classes of antiplatelet drugs such as prasugrel, which acts on the P2Y12 ADP receptor , not the Gp IIb/IIIa receptor.</li><li>\u27a4 recognize the classification of antiplatelet agents</li><li>\u27a4 distinguishing between Gp IIb/IIIa inhibitors (abciximab, tirofiban, and eptifibatide)</li><li>\u27a4 other classes of antiplatelet drugs</li><li>\u27a4 prasugrel,</li><li>\u27a4 acts on</li><li>\u27a4 P2Y12 ADP receptor</li><li>\u27a4 ANTIPLATELET DRUGS</li><li>\u27a4 ANTIPLATELET DRUGS</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3f1aa78d",
      "audio": ""
    },
    {
      "text": "What is the recommended management for a patient who experiences excessive bleeding after receiving fibrinolytic therapy for an acute myocardial infarction?",
      "options": [
        {
          "label": "A",
          "text": "Epsilon Aminocaproic acid",
          "correct": true
        },
        {
          "label": "B",
          "text": "Protamine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Heparin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Streptokinase",
          "correct": false
        }
      ],
      "correct_answer": "A. Epsilon Aminocaproic acid",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. Epsilon Aminocaproic acid</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Protamine: This is incorrect as protamine is used to reverse the effects of heparin, not fibrinolytic therapy.</li><li>\u2022 Option B. Protamine:</li><li>\u2022 incorrect as protamine</li><li>\u2022 reverse the effects of heparin,</li><li>\u2022 Option C. Heparin: This is incorrect as heparin is an anticoagulant and would exacerbate bleeding.</li><li>\u2022 Option C. Heparin:</li><li>\u2022 incorrect as heparin</li><li>\u2022 anticoagulant</li><li>\u2022 Option D. Streptokinase: This is incorrect as streptokinase is a fibrinolytic agent , not an antidote.</li><li>\u2022 Option D. Streptokinase:</li><li>\u2022 incorrect</li><li>\u2022 streptokinase is a fibrinolytic agent</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Epsilon aminocaproic acid is used to manage excessive bleeding by inhibiting fibrinolysis following fibrinolytic therapy in acute myocardial infarction. It is a lysine analog that prevents plasminogen from binding to fibrin, thereby reducing the breakdown of fibrin clots.</li><li>\u2022 Epsilon aminocaproic acid</li><li>\u2022 excessive bleeding by inhibiting fibrinolysis</li><li>\u2022 fibrinolytic therapy</li><li>\u2022 acute</li><li>\u2022 myocardial infarction.</li><li>\u2022 lysine</li><li>\u2022 prevents plasminogen from binding to fibrin,</li><li>\u2022 reducing the breakdown of</li><li>\u2022 fibrin clots.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f86233d6",
      "audio": ""
    },
    {
      "text": "Which of the following is a antagonist of PAR-1 receptors of thrombin?",
      "options": [
        {
          "label": "A",
          "text": "Prasugrel",
          "correct": false
        },
        {
          "label": "B",
          "text": "Ticlopidine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Tirofiban",
          "correct": false
        },
        {
          "label": "D",
          "text": "Vorapaxar",
          "correct": true
        }
      ],
      "correct_answer": "D. Vorapaxar",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D. Vorapaxar</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A : Prasugrel is a P2Y12 adenosine diphosphate receptor inhibitor, not a PAR-1 inhibitor.</li><li>\u2022 Option A</li><li>\u2022 : Prasugrel</li><li>\u2022 P2Y12 adenosine diphosphate receptor inhibitor,</li><li>\u2022 Option B: Ticlopidine is also a P2Y12 adenosine diphosphate receptor inhibitor, used less commonly due to side effects.</li><li>\u2022 Option B:</li><li>\u2022 Ticlopidine</li><li>\u2022 P2Y12 adenosine diphosphate receptor inhibitor,</li><li>\u2022 Option C: Tirofiban is a glycoprotein IIb/IIIa inhibitor that blocks fibrinogen binding and platelet aggregation, not a PAR-1 antagonist.</li><li>\u2022 Option C:</li><li>\u2022 Tirofiban</li><li>\u2022 glycoprotein IIb/IIIa</li><li>\u2022 blocks fibrinogen</li><li>\u2022 binding and platelet aggregation,</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Vorapaxar is a PAR-1 antagonist that inhibits platelet aggregation by preventing thrombin from binding to PAR-1 on platelets, offering a therapeutic approach in the prevention of thrombotic cardiovascular events.</li><li>\u2022 Vorapaxar</li><li>\u2022 PAR-1 antagonist</li><li>\u2022 inhibits platelet aggregation</li><li>\u2022 preventing thrombin</li><li>\u2022 binding to PAR-1 on platelets,</li><li>\u2022 prevention of thrombotic cardiovascular events.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5e175ec3",
      "audio": ""
    },
    {
      "text": "Heparin acts via activation of which of the following molecules?",
      "options": [
        {
          "label": "A",
          "text": "Anti-thrombin III",
          "correct": true
        },
        {
          "label": "B",
          "text": "Protein C",
          "correct": false
        },
        {
          "label": "C",
          "text": "Protein S",
          "correct": false
        },
        {
          "label": "D",
          "text": "Thrombomodulin",
          "correct": false
        }
      ],
      "correct_answer": "A. Anti-thrombin III",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. Anti-thrombin III</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B: Protein C: Protein C is a natural anticoagulant that is activated by thrombomodulin , a protein expressed on the surface of endothelial cells . Protein C inactivates factors V and VIII, which are involved in the clotting process . Heparin does not directly activate protein C.</li><li>\u2022 Option B: Protein C:</li><li>\u2022 natural anticoagulant</li><li>\u2022 activated by thrombomodulin</li><li>\u2022 protein</li><li>\u2022 surface of</li><li>\u2022 endothelial cells</li><li>\u2022 Protein C inactivates factors V and VIII,</li><li>\u2022 involved</li><li>\u2022 clotting process</li><li>\u2022 Heparin does not</li><li>\u2022 activate protein C.</li><li>\u2022 Option C: Protein S: Protein S is a cofactor for protein C, which enhances its activity. Heparin does not directly a ctivate protein S.</li><li>\u2022 Option C: Protein S:</li><li>\u2022 cofactor for protein C,</li><li>\u2022 enhances its activity.</li><li>\u2022 Heparin does not</li><li>\u2022 ctivate protein S.</li><li>\u2022 Option D: Thrombomodulin: Thrombomodulin is a protein expressed on the surface of endothelial cells that binds to and activates protein C . Heparin does not directly activate thrombomodulin.</li><li>\u2022 Option D: Thrombomodulin:</li><li>\u2022 Thrombomodulin</li><li>\u2022 protein</li><li>\u2022 surface of endothelial cells</li><li>\u2022 binds to</li><li>\u2022 activates</li><li>\u2022 protein C</li><li>\u2022 Heparin</li><li>\u2022 does not</li><li>\u2022 activate thrombomodulin.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Heparin acts by enhancing the activity of anti-thrombin III, which inhibits clotting factors such as thrombin and factor Xa.</li><li>\u2022 Heparin</li><li>\u2022 enhancing the activity of anti-thrombin III,</li><li>\u2022 inhibits clotting factors</li><li>\u2022 thrombin and factor Xa.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4a00137d",
      "audio": ""
    },
    {
      "text": "Warfarin induced skin necrosis is seen in.",
      "options": [
        {
          "label": "A",
          "text": "Protein C deficiency",
          "correct": true
        },
        {
          "label": "B",
          "text": "Sickle cell anaemia",
          "correct": false
        },
        {
          "label": "C",
          "text": "Factor V leiden deficiency",
          "correct": false
        },
        {
          "label": "D",
          "text": "Antithrombin 3 deficiency",
          "correct": false
        }
      ],
      "correct_answer": "A. Protein C deficiency",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. Protein C deficiency</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Sickle cell anaemia: Sickle cell anaemia is not associated with warfarin-induced skin necrosis . Skin manifestations in sickle cell disease are typically related to vaso-occlusive crises and may include painful swelling of the hands and feet (dactylitis), leg ulcers, and skin infections.</li><li>\u2022 Option B. Sickle cell anaemia:</li><li>\u2022 not</li><li>\u2022 warfarin-induced skin necrosis</li><li>\u2022 Skin manifestations</li><li>\u2022 vaso-occlusive crises</li><li>\u2022 painful swelling of the hands and feet (dactylitis), leg ulcers,</li><li>\u2022 skin infections.</li><li>\u2022 Option C. Factor V Leiden deficiency: Factor V Leiden deficiency is not associated with warfarin-induced skin necrosis. Factor V Leiden mutation predisposes individuals to thrombosis by making them resistant to the anticoagulant effects of activated protein C.</li><li>\u2022 Option C. Factor V Leiden deficiency:</li><li>\u2022 not</li><li>\u2022 warfarin-induced skin necrosis.</li><li>\u2022 Factor V</li><li>\u2022 Leiden mutation</li><li>\u2022 thrombosis</li><li>\u2022 resistant to the anticoagulant effects</li><li>\u2022 activated protein C.</li><li>\u2022 Option D. Antithrombin 3 deficiency: Antithrombin 3 deficiency is not associated with warfarin-induced skin necrosis. Antithrombin deficiency increases the risk of thrombosis due to impaired inhibition of coagulation factors , but it does not predispose individuals to warfarin-induced skin necrosis.</li><li>\u2022 Option D. Antithrombin 3 deficiency:</li><li>\u2022 not</li><li>\u2022 warfarin-induced skin necrosis. Antithrombin</li><li>\u2022 deficiency</li><li>\u2022 increases the risk of thrombosis</li><li>\u2022 impaired inhibition of coagulation factors</li><li>\u2022 does not</li><li>\u2022 warfarin-induced skin necrosis.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Warfarin-induced skin necrosis is primarily seen in patients with underlying protein C deficiency or other risk factors, characterized by the development of painful necrotic lesions, especially in areas with high adipose tissue concentration.</li><li>\u2022 Warfarin-induced skin necrosis</li><li>\u2022 underlying protein C deficiency</li><li>\u2022 development of painful necrotic lesions,</li><li>\u2022 high adipose tissue concentration.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1cdf67ff",
      "audio": ""
    },
    {
      "text": "Based on the mechanism of action shown in figure, Drug X is likely to be:",
      "options": [
        {
          "label": "A",
          "text": "Aspirin",
          "correct": true
        },
        {
          "label": "B",
          "text": "Clopidogrel",
          "correct": false
        },
        {
          "label": "C",
          "text": "Abciximab",
          "correct": false
        },
        {
          "label": "D",
          "text": "Atopaxar",
          "correct": false
        }
      ],
      "correct_answer": "A. Aspirin",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/picture10.jpg"
      ],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/picture12.jpg"
      ],
      "explanation": "<p><strong>Ans. A. Aspirin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Clopidogrel: Clopidogrel is an ADP receptor inhibitor. It inhibits the P2Y12 receptor on the platelet surface, which is involved in ADP-induced platelet activation and aggregation. This mechanism is not consistent with the action of Drug X in the diagram.</li><li>\u2022 Option B. Clopidogrel: Clopidogrel is an ADP receptor inhibitor. It inhibits the P2Y12 receptor on the platelet surface, which is involved in ADP-induced platelet activation and aggregation. This mechanism is not consistent with the action of Drug X in the diagram.</li><li>\u2022 Option C. Abciximab: Abciximab is a glycoprotein IIb/IIIa inhibitor. It binds to the glycoprotein IIb/IIIa receptor on the platelet surface, preventing fibrinogen binding and platelet aggregation. This action does not involve the COX pathway and therefore does not correspond to Drug X.</li><li>\u2022 Option C. Abciximab:</li><li>\u2022 Abciximab is a glycoprotein IIb/IIIa inhibitor. It binds to the glycoprotein IIb/IIIa receptor on the platelet surface, preventing fibrinogen binding and platelet aggregation.</li><li>\u2022 action does not</li><li>\u2022 COX pathway</li><li>\u2022 not</li><li>\u2022 Drug X.</li><li>\u2022 Option D. Atopaxar: Atopaxar is a protease-activated receptor-1 (PAR-1) antagonist. It inhibits thrombin receptor signaling on platelets . Sinc e Drug X is shown acting on the COX pathway, Atopaxar is not the correct answer.</li><li>\u2022 Option D. Atopaxar:</li><li>\u2022 Atopaxar</li><li>\u2022 protease-activated receptor-1 (PAR-1) antagonist.</li><li>\u2022 inhibits</li><li>\u2022 thrombin receptor signaling</li><li>\u2022 platelets</li><li>\u2022 e Drug X</li><li>\u2022 shown acting</li><li>\u2022 COX pathway,</li><li>\u2022 Atopaxar</li><li>\u2022 not</li><li>\u2022 correct answer.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational objective is to identify antiplatelet drugs based on their mechanism of action , specifically recognizing the unique action of aspirin on the COX-1 enzyme leading to the inhibition of thromboxane A2 synthesis and subsequent platelet aggregation.</li><li>\u27a4 identify antiplatelet drugs</li><li>\u27a4 mechanism of action</li><li>\u27a4 action of aspirin</li><li>\u27a4 COX-1 enzyme</li><li>\u27a4 inhibition of thromboxane A2 synthesis and subsequent platelet aggregation.</li><li>\u27a4 Antiplatelet Drugs</li><li>\u27a4 Antiplatelet Drugs</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d82f14c0",
      "audio": ""
    },
    {
      "text": "Which among the following is an orally active anti thrombin drug?",
      "options": [
        {
          "label": "A",
          "text": "Hirudin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Argatroban",
          "correct": false
        },
        {
          "label": "C",
          "text": "Bivalirudin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Dabigatran",
          "correct": true
        }
      ],
      "correct_answer": "D. Dabigatran",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D. Dabigatran</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Hirudin: Hirudin is a naturally occurring peptide from the medicinal leech that directly inhibits thrombin. However, it is not orally active.</li><li>\u2022 Option A. Hirudin:</li><li>\u2022 naturally occurring peptide</li><li>\u2022 medicinal leech</li><li>\u2022 directly inhibits thrombin.</li><li>\u2022 not orally active.</li><li>\u2022 Option B. Argatroban: Argatroban is a synthetic direct thrombin inhibitor , but it is administered intravenously and not orally.</li><li>\u2022 Option B. Argatroban:</li><li>\u2022 synthetic direct thrombin inhibitor</li><li>\u2022 administered intravenously</li><li>\u2022 Option C. Bivalirudin: Bivalirudin is another direct thrombin inhibitor that is used intravenously, particularly during percutaneous coronary interventions , and is not taken orally.</li><li>\u2022 Option C. Bivalirudin:</li><li>\u2022 another direct thrombin inhibitor</li><li>\u2022 intravenously,</li><li>\u2022 percutaneous</li><li>\u2022 coronary interventions</li><li>\u2022 not taken orally.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational objective is to recognize the different anticoagulant drugs available for thrombin inhibition and to understand their routes of administration . Distinguishing between orally active and non-orally active anticoagulants is essential for proper patient management and treatment planning.</li><li>\u27a4 anticoagulant drugs</li><li>\u27a4 thrombin inhibition</li><li>\u27a4 routes of administration</li><li>\u27a4 orally active and non-orally active anticoagulants</li><li>\u27a4 proper patient</li><li>\u27a4 management and treatment planning.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8152a716",
      "audio": ""
    }
  ]
}